Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers
Sponsor: Ashvattha Therapeutics, Inc.
A PHASE1/PHASE2 clinical study on Alzheimer Disease (AD) and Amyotrophic Lateral Sclerosis (ALS), this trial is actively recruiting participants. The trial is conducted by Ashvattha Therapeutics, Inc. and has accumulated 7 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2023 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
▶ Show 2 earlier versions
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ashvattha Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .